(48 days)
The Advance Image Enhancement, Inc.'s Region of Interest Image Enhancement software is intended to improve the sharpness and clarity of subtle image features. The device used with FDA cleared monitors may be used by a trained physician or healthcare professional for display. manipulation and interpretation of lossless compressed mammographic images for screening and diagnostic mammography, as well as any other DICOM multi-modality image.
The AIE software is intended as an added tool residing on any DICOM image workstation for improving the radiologist's perception of image features on any lossless compressed or noncompressed multi-modality DICOM "for-presentation" image. This software would be used while the radiologist is reviewing magnification window image segments on FDA cleared monitors and is intended to complement existing DICOM image workstation functionality.
Warning: Lossy compressed mammographic images and digitized film screen images must not be reviewed for primary image interpretations. Mammographic images may only be interpreted using an FDA approved monitor that offers at least 5 Mpixel resolution and meets other technical specifications reviewed and accepted by FDA.
The Region of Interest Image Enhancement for Digital Mammography (ROILE-DM) software created by Advanced Image Enhancement, Inc. is intended to improve the overall ability of an image reader to resolve abnormalities with greater confidence in their findings. The AIE software is intended to improve the sharpness and clarity of subtle image features. The device used with FDA cleared monitors may be used by a trained physician for display, manipulation and interpretation of lossless compressed or noncompressed mammographic images for screening and diagnostic mammography, as well as any other DICOM multi-modality image. The intended operational environment is the radiology reading room or any other FDA approved environment.
Here's an analysis of the acceptance criteria and study details based on the provided text for device K062059:
The provided submission does not explicitly state acceptance criteria in a quantitative or pass/fail format. Instead, it describes a comparative study against a predicate device to demonstrate substantial equivalence and establish that the device is safe and effective for its intended use. The "acceptance criteria" are implicitly met if the study demonstrates substantial equivalence to the predicate device.
1. Table of Acceptance Criteria and Reported Device Performance
| Acceptance Criteria (Implicit) | Reported Device Performance |
|---|---|
| Substantial equivalence to predicate device (Hologic, Inc.'s SecureView DX Softcopy Workstation) for intended use. | The study showed that the AIE Region of Interest Enhancement Software is substantially equivalent to the predicate device. |
| Safe and effective for its intended use (improving sharpness and clarity of subtle image features in mammography for trained physicians). | The information provided in the premarket notification submission demonstrated that the device is safe and effective for its intended use. |
2. Sample Size Used for the Test Set and Data Provenance
- Sample Size for Test Set: 50 mammography cases.
- Data Provenance: Not explicitly stated (e.g., country of origin, retrospective or prospective).
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
The text describes a "reader study," but it does not specify how ground truth was established for the 50 mammography cases. The 6 radiologists performed a "features analysis comparing" the devices, implying they were evaluating the images themselves rather than establishing a separate ground truth.
- Number of Experts for Ground Truth: Not explicitly stated, as the study description focuses on reader comparison rather than ground truth establishment by these readers.
- Qualifications of Experts: 6 MQSA certified Radiologists.
4. Adjudication Method for the Test Set
Not specified. The study description states they "performed a features analysis comparing" the devices, but it doesn't detail any adjudication method for reaching a consensus or ground truth among the readers.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and the Effect Size of How Much Human Readers Improve with AI vs Without AI Assistance
- MRMC Comparative Effectiveness Study: Yes, a reader study was conducted where "6 MQSA certified Radiologists... performed a features analysis comparing the AIE Region of Interest Enhancement Software to the predicate device on 50 mammography cases." This implies a comparative study between the two software tools.
- Effect Size of Human Readers Improvement with AI vs. Without AI Assistance: The document does not provide a quantitative "effect size" or a direct comparison of readers with and without AI assistance. The comparison was between the AIE software and a predicate device (Hologic SecureView DX Softcopy Workstation). The study concluded substantial equivalence, suggesting comparable performance, but no metrics on specific improvement are given.
6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) Was Done
No, the device is described as an "added tool residing on any DICOM image workstation for improving the radiologist's perception" and is "used by a trained physician" for display, manipulation, and interpretation. The clinical testing performed was a reader study. There is no indication of a standalone algorithm performance evaluation.
7. The Type of Ground Truth Used
The document does not explicitly state the type of ground truth used for the 50 mammography cases in the reader study. Since the study involved radiologists comparing features, it's possible that the "ground truth" was based on established clinical findings or a reference standard that was not explicitly detailed in this summary. However, it is not stated as pathology, outcome data, or expert consensus specifically.
8. The Sample Size for the Training Set
Not applicable. The description is of a 510(k) submission, which focuses on demonstrating device safety and effectiveness, often through comparison to a predicate. It does not provide details about the development or training of the AIE software.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as no information regarding a training set or its ground truth establishment is provided in the document.
{0}------------------------------------------------
K06205'9
AIE
Advanced Image Enhancement, Inc. Region of Interest Image Enhancement for Digital Mammography Traditional 510(k) Submission
Section 5: 510(k) Summary
Submitter: Advanced Image Enhancement 306 Valentine Street Fall River, MA 02720 Contact Person: Jillian M. Reed Consultant Reed Technical Associates, LLC Date Prepared: July 19, 2006 Classification Name: Picture Archiving and Communications System Proprietary Name: Advance Image Enhancement, Inc.'s Region of Interest Image Enhancement Software Predicate Devices: Hologic, Inc.'s SecureView DX Softcopy Workstation (#K041555)
Device Description:
The Region of Interest Image Enhancement for Digital Mammography (ROILE-DM) software created by Advanced Image Enhancement, Inc. is intended to improve the overall ability of an image reader to resolve abnormalities with greater confidence in their findings. The AIE software is intended to improve the sharpness and clarity of subtle image features. The device used with FDA cleared monitors may be used by a trained physician for display, manipulation and interpretation of lossless compressed or noncompressed mammographic images for screening and diagnostic mammography, as well as any other DICOM multi-modality image. The intended operational environment is the radiology reading room or any other FDA approved environment.
Intended Use:
The Advance Image Enhancement, Inc.'s Region of Interest Image Enhancement software is intended to improve the sharpness and clarity of subtle image features. The device used with FDA cleared monitors may be used by a trained physician or healthcare professional for display, manipulation and interpretation of lossless compressed or non-compressed mammographic images for screening and diagnostic mammography, as well as any other DICOM multi-modality image.
The AIE software is intended as an added tool residing on any DICOM image workstation for improving the radiologist's perception of image features on any lossless compressed multi-modality DICOM "for-presentation" image. This software would be used while the radiologist is reviewing magnification window image segments on FDA cleared monitors and is intended to complement existing DICOM image workstation functionality.
Warning: Lossy compressed mammographic images and digitized film screen images must not be reviewed for primary image interpretations. Mammographic images may only be interpreted using an FDA approved monitor that offers at least 5 Mpixel resolution and meets other technical specifications reviewed and accepted by FDA.
SEP - 6 2006
{1}------------------------------------------------
Image /page/1/Picture/0 description: The image shows the letters AIE in a bold, sans-serif font. The letters are arranged horizontally, with 'A' on the left, 'I' in the middle, and 'E' on the right. The letters are all capitalized and appear to be printed in black ink on a white background. The letters are closely spaced together.
Advanced Image Enhancement, Inc. Region of Interest Image Enhancement for Digital Mammography Traditional 510(k) Submission
Substantial Equivalence:
Testing performed has shown that Advanced Image Enhancement, Inc.'s Region of Interest Image Enhancement Software is substantially equivalent to the Hologic, Inc. 's SecureView DX Softcopy Workstation for its intended use.
Discussion of Non-Clinical Testing Performed:
Thorough system verification and validation testing was performed to ensure the safe and effective use of the AIE Region of Interest Enhancement Software.
Discussion of Clinical Testing Performed:
A reader study, comprised of 6 MQSA certified Radiologists, was conducted where they performed a features analysis comparing the AIE Region of Interest Enhancement Software to the predicate device on 50 mammography cases.
Conclusions:
The information provided in this premarket notification submission has shown that the AIE Region of Interest Image Enhancement Software is substantially equivalent to the predicate device and is safe and effective for its intended use.
{2}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird-like figure with three curved lines representing its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the bird-like figure.
Food and Drug Administration 9200 Corporate Blvd. Rockville MD 20850
SEP - 6 2006
Advanced Image Enhancement, Inc. c/o Ms. Jillian Reed Regulatory and Clinical Affairs Consultant Reed Technical Associates, LLC 25 Walnut Street MONROE CT 06468
Re: K062059
Trade/Device Name: Advance Image Enhancement, Inc.'s Region of Interest Image Enhancement Software Regulation Number: 21 CFR §892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: II Product Code: LLZ Dated: July 19, 2006 Received: July 20, 2006
Dear Ms. Reed:
We have reviewed your Section 510(k) premarket notification of intent to market the device wt nave reviewed your becally be device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce use stated in the encreases to the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic have been roctablines approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good controls provibitions of a labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket IT your device is olassified (500 a00 (1) ifitional controls. Existing major regulations affecting your Apploval), it may of subject to aderal Regulations, Title 21, Parts 800 to 898. In addition, FDA device build be round announcements concerning your device in the Federal Register.
Image /page/2/Picture/10 description: The image shows a circular logo for the FDA Centennial, celebrating 100 years from 1906-2006. The logo features the FDA acronym prominently in the center. Below the acronym, the word "Centennial" is written in cursive. Three stars are arranged below the word "Centennial".
ting and Promoting Public Hoalth
{3}------------------------------------------------
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:
| 21 CFR 876.xxx | (Gastroenterology/Renal/Urology | 240-276-011. |
|---|---|---|
| 21 CFR 884.xxx | (Obstetrics/Gynecology) | 240-276-011. |
| 21 CFR 894.xxx | (Radiology) | 240-276-0120 |
| Other | 240-276-0100 |
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150
or at its Internet address http://www.fda.gov/cdrl/industry/support/index.html.
Sincerely yours,
Nancy C Hodgdon
Nancy C. Brogdon Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
Indications for Use
510(k) Number (if known): K062059
Advance Image Enhancement, Inc.'s Region of Interest Image Enhancement Software Device Name:
Indications for Use:
The Advance Image Enhancement, Inc.'s Region of Interest Image Enhancement software is intended to improve the sharpness and clarity of subtle image features. The device used with FDA cleared monitors may be used by a trained physician or healthcare professional for display. manipulation and interpretation of lossless compressed mammographic images for screening and diagnostic mammography, as well as any other DICOM multi-modality image.
The AIE software is intended as an added tool residing on any DICOM image workstation for improving the radiologist's perception of image features on any lossless compressed or noncompressed multi-modality DICOM "for-presentation" image. This software would be used while the radiologist is reviewing magnification window image segments on FDA cleared monitors and is intended to complement existing DICOM image workstation functionality.
Warning: Lossy compressed mammographic images and digitized film screen images must not be reviewed for primary image interpretations. Mammographic images may only be interpreted using an FDA approved monitor that offers at least 5 Mpixel resolution and meets other technical specifications reviewed and accepted by FDA.
Prescription Use XXX (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Nancy C. Brogdon
Page 1 of 1
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).